Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Cox multivariate analysis for PFS

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

  Progression-free survival (PFS)
HR (95% CI) p value
DCR axitinib 0.171 (0.107–0.272) < 0.0000001
DCR sunitinib 0.549 (0.308–0.977) 0.041
Heng score
 Good prognosis 1   0.174
 Poor prognosis 1.909 (0.964–3.779) 0.064
 Intermediate 1.249 (0.752–2.073) 0.391
Nephrectomy
 Yes 0.572 (0.305–1.072) 0.081
Gender
 Male 0.567 (0.378–0.851) 0.006